Peptides for arthritis and joint pain: what actually works?

Bottom line: There is no proven injectable “joint-regeneration peptide” that erases osteoarthritis. But peptide-related approaches are not all fiction: semaglutide produced a large pain improvement in a specific group with obesity and knee arthritis, while oral collagen shows a smaller, less certain benefit across several trials.

Best direct trial: Semaglutide in 407 adults with obesity and moderate knee osteoarthritis.
Most accessible option: Oral collagen supplements, with favorable but inconsistent trial evidence.
Biggest evidence gap: BPC-157 and similar “healing” injections marketed as if animal research were a human result.

First, identify what is driving the joint pain

“Arthritis” can describe different diseases. Osteoarthritis, rheumatoid arthritis, gout, referred pain, tendon disease, and nerve pain do not have the same cause or treatment. A serious plan starts with the pattern, examination, and appropriate testing—not with a vial chosen from a list.

The strongest peptide-related result

In the STEP 9 randomized trial, people with obesity and knee osteoarthritis received semaglutide or placebo in addition to diet and activity counseling. At 68 weeks, the average WOMAC pain score fell by 41.7 points with semaglutide and 27.5 points with placebo. Weight fell by 13.7% and 3.2%, respectively.

That is a meaningful result, but it applies to a defined population: people with obesity and moderate-to-severe knee-arthritis pain. The study does not show that semaglutide repairs cartilage or treats every painful joint.

Read the full STEP 9 evidence summary.

What about collagen peptides?

An updated meta-analysis combined 11 randomized trials with 870 participants and found improvements in pain and function. Earlier reviewers also warned about heterogeneity and bias. The fair conclusion is “possibly useful for symptoms,” not “rebuilds your knees.”

Read the collagen evidence summary.

What about BPC-157?

BPC-157 is promoted with confident words—repair, recovery, regeneration—but reliable human results have not caught up. FDA’s July 2026 review described five small human studies and only one retrospective knee-pain report involving 17 people. That cannot establish effectiveness.

Our verdict: Peptide science may widen the options for joint pain, especially when metabolic health and joint load are part of the problem. But any clinic selling “regeneration” without showing controlled human outcomes is selling certainty the evidence does not provide.

Primary sources

STEP 9: semaglutide in people with obesity and knee osteoarthritis (2024; 407 participants)
Updated meta-analysis of collagen supplementation for knee osteoarthritis (11 trials; 870 participants)
FDA briefing document on BPC-157 (July 2026)

Last reviewed August 11, 2026. This page compares evidence; it does not select treatment for an individual.